Covid-19 Clinical Trial
Official title:
Covid-19: Possible Role of Neutrophil Extracellular Traps
The process by which neutrophils expel DNA together with various proteins to the outside,
forming a network structure called Neutrophil Extracellular Traps (NETs) constitutes a
particular cell death that involves the destruction of the nuclear membrane before the
plasmatic one. This process is called NETosis and differs from other known forms of cell
death, such as necrosis and apoptosis.
This process, however, if exaggerated, brings local or systemic damage. Viruses are known for
their ability to evade the body's immune response. Only recently has it been seen that they
can act as triggers for NETosis process.
In fact, many viruses can stimulate neutrophils to produce NETs. Virus-induced NETs can begin
to circulate in an uncontrolled manner, leading to an extreme systemic response of the body
with the production of immunocomplexes, cytokines, Interferon I etc.
To date, there are no data in the literature on the role of NETs in Covid-19 infection, a
viral infection that leads to highly lethal interstitial pneumonia and for which there is
currently no vaccine or specific therapy.
Advanced forms of Covid-19 are often characterized by hyperinflammation ("cytokine storm")
with the development of an ARDS-like condition. Furthermore, reports of micro and macro
thrombotic phenomena such as microangiopathy, pulmonary embolism (which has led to a careful
evaluation procedure for antithrombotic prophylaxis and/or coagulation in Covid-19 patients)
are increasingly frequent.
The primary objective of the study is to understand if NETs can be implicated in the response
to Covid-19 and by which mechanisms. Concrete therapeutic proposals could derive from the
knowledge and enhancement of this form of innate immunity.
To do this, it will be necessary to evaluate the activity of NETosis in Covid-19 patients and
evaluate whether the clinical course of the disease (worsening vs healing) determines the
degree of NETosis activity. Therefore, the association between mortality from
Covid-19/survival and NETs activity will be studied.
Secondary objectives concern the possibility of studying the associations among NETosis
markers and blood inflammation markers and among NETosis markers and the onset of peripheral
or deep vein thrombosis.
Finally, the possibility that the plasma deriving from Covid-19 patients could trigger the
NETosis process in vitro will be evaluated.
The process by which neutrophils expel DNA together with various proteins to the outside,
forming a network structure called Neutrophil Extracellular Traps (NETs) constitutes a
particular cell death that involves the destruction of the nuclear membrane before the
plasmatic one. This process is called NETosis and differs from other known forms of cell
death, such as necrosis and apoptosis.
Neutrophil death by NETs ejection (NETosis) was first described in 2004 by Brinkman.
NETs,as indicated by the word itself, represent a sort of network composed of DNA fibers,
histones and proteins derived from the neutrophil granules, whose main function is to trap
pathogens (mainly bacteria and fungi).This process is related to the innate immunity.
However, this process, if activated in an exaggerated way, implies itself local or systemic
damage.
The DNA expelled during this process is a double stranded DNA, a dsDNA subtype. The dsDNA,
which represents a fraction of the DNA available in the circulation (cell free DNA - cfDNA),
originates from various processes of cell death, and is therefore correlated with the degree
of tissue damage. It is present only in small quantities in healthy subjects.
It is important to underline how during the NETosis process the cellular redox state is
altered, leading to an excess production of oxygen free radicals (Reactive Oxygen Species,
ROS) and to the activation of the enzyme NADPH oxidase. The formation of NETs, and therefore
the process of NETosis, were initially studied in the context of bacterial infections, but
subsequently their role became increasingly clear in other conditions such as cancer,
autoimmune diseases, lung diseases, atherosclerosis and venous thromboembolic disease.
In particular, NETosis seems to play an important role in all conditions characterized by
venous and arterial thrombosis, as numerous evidences have confirmed.
NETosis has also been documented at the microvascular level, such as in vasculitis,
thrombotic microangiopathies such as Moschowitz syndrome.
Viruses are known for their ability to evade the body's immune response. Recently it has been
seen that they too can act as triggers of NETosis processes.
In fact, many viruses can stimulate neutrophils to produce NETs. Different responses of
neutrophils have been seen, from classical NETosis, to the production of antiviral agents or
even to the switch to apoptosis.
Virus-induced NETs (therefore complexes of dsDNA, histones, granular proteins) can begin to
circulate in an uncontrolled way, leading to an extreme systemic response of the body with
the production of immune complexes, cytokines, Interferon I etc.
NETosis appears to be closely linked to the inflammatory response. For example, it is known
that in the neutrophilic granulocyte the PAD4 protein is present in the nucleus, it
decondensates the chromatin and favors the formation of the NETs. On the other hand, NETs
increase in patients with acute respiratory distress syndrome (ARDS) as observed in studies
about bronchoalveolar lavage fluid, as well as in patients with acute respiratory failure
during COPD exacerbation.
It is therefore clear that virus-induced NETosis acts as a double-edged sword: if on one hand
there is the mechanical entrapment of the virus, on the other the inflammatory and
immunological reaction triggered by the release of the NETs can be harmful itself.
To date, there are few data in the literature on the role of NETs in Covid-19 infection, a
viral infection that can lead to highly lethal interstitial pneumonia and for which there is
no vaccine or specific therapy today. Advanced forms of Covid-19 are often characterized by
hyperinflammation ("cytokine storm") with the development of an ARDS-like condition.
Furthermore, reports of micro and macro thrombotic phenomena such as microangiopathy,
pulmonary embolism (which has led to a careful evaluation procedure for antithrombotic
prophylaxis and / or coagulation in Covid-19 patients) are increasingly frequent.
OBJECTIVE OF THE STUDY The primary objective of the study is to understand if NETs can be
implicated in the response to Covid-19 and by which mechanisms. Concrete therapeutic
proposals could derive from the knowledge and enhancement of this form of innate immunity.
To do this, it will be necessary to evaluate the activity of NETosis in Covid-19 patients and
evaluate whether the clinical course of the disease (worsening vs healing) determines the
degree of NETosi activity. Therefore, the association between mortality from
Covid-19/survival and NETs activity will be studied.
Secondary objectives concern the possibility of studying the various associations among
NETosis markers and biohumoral indices of inflammation and among NETosi markers and the onset
of peripheral or deep vein thrombosis.
Finally, the possibility that the plasma from Covid-19 patients could trigger the NETosis
process in vitro will be evaluated.
PLANNED PROCEDURES and COLLECTED INFORMATION Medical examination: (blood pressure, heart rate
and SpO2, which will allow to evaluate the precise PaO2 / FiO2 ratio).
As in normal clinical practice, Covid-19 patients will undergo venous sampling for the
determination of blood count, creatinine, lipid profile, PCR, D-dimer, LDH, liver function
indices and blood glucose.
Precise medical history will be drawn up for each subject. Patients will
undergo:electrocardiogram and chest x-ray and, in selected cases, chest CT scan, depending on
their clinical need.
They will also undergo venous echo-color Doppler lower limbs examination. A complete analysis
of the venous axes will not be necessary. NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the
cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.
Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes)
will be collected and the detection of NETs at electron microscopy will be assessed.
Informed consent will be requested.
CALCULATION OF THE SAMPLE The sample size was defined on the basis of the number of
admissions for Covid-19 in the months of March-April 2020 and on the decrease in numbers in
the current period.
100 subjects (50 patients and 50 controls) are expected to be enrolled.
STATISTICAL ANALYSIS Hypothetical statistical analysis: the data will be collected through
descriptive statistics. The estimates will be accompanied by appropriate 95% confidence
intervals. The level of statistical significance is set at 5%. The statistical program Stata
14.2 will be used. Planned test: t-test and Mann-Whitney test. Correlations will be evaluated
through Pearson or Spearman coefficients. Furthermore, Kaplan-Meier analyzes will be carried
out with the use of Log-Rank test and Cox regression for survival analysis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|